Latex Medical Gloves - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the latex medical gloves market size is expected to grow from USD 2.72 billion in 2025 to USD 2.91 billion in 2026 and is forecast to reach USD 4.07 billion by 2031 at 6.94% CAGR over 2026-2031.

This report is Segmented by Product Type (Sterile Gloves, Non-Sterile Gloves), Form (Powder-Free Gloves, Powdered Gloves), Application (Examination Gloves, Surgical Gloves), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Diagnostic Laboratories, Others), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Latex Medical Gloves Market Trends and Insights

Rising Post-Pandemic Institutional Demand for Single-Use PPE

Global glove consumption normalized to 357 billion pieces in 2024, only 6% below the 2021 peak, yet excess capacity from Chinese plants in Vietnam and Indonesia holds down average selling prices. Hospital groups now emphasize supply resilience, exemplified by Medline's USD 6.26 billion IPO proceeds earmarked for domestic manufacturing and predictive logistics. The U.S. Department of Justice's Project Airbridge precedent supports distributor-led coordination that continues to guide procurement rules. Cardinal Health disclosed USD 491 million latex exposure in 2024, confirming raw-material volatility as a margin risk. Front-loading by U.S. buyers ahead of tariff hikes boosted Hartalega's late-2024 revenue but created a volume trough in early-2025, illustrating how policy uncertainty distorts quarterly demand.

Mandatory Double-Gloving Protocols in High-Risk Surgeries

Surgical puncture incidence exceeds 30% under single-layer use, and although WHO guidelines stop short of mandating double-gloving, leading teaching hospitals enforce it, driving higher per-case glove consumption. Surgical-grade gloves featuring puncture-indicator systems are replacing standard white gloves and carry a 10-15% premium. Sri Trang's 2024 patent for low-zinc-oxide latex reduces metal migration below 5 mg/kg, targeting extended-wear surgical scenarios. CMS proposals that reimburse U.S.-made nitrile but not latex gloves add policy headwinds, yet tactile sensitivity keeps latex favored among surgeons. As hospitals refine infection-control metrics, color-coded indicator gloves are emerging as a de-facto standard in orthopedics and trauma theaters.

Natural-Rubber Price Volatility & Smallholder Supply Shocks

Hartalega's H1 2024 margins shrank even as revenue climbed 39% because a stronger Malaysian ringgit muted ASP gains and raw-material costs spiked during the wintering season. Smallholders supplying 85% of global latex suffer labor shortages, cutting tapping frequency, while aging tree stock heightens structural under-supply risk. Spot prices surged 15-20% during the May-July 2024 wintering phase, only easing after seasonal recovery. Although Maybank forecasts easing costs, replanting deficits signal recurrent volatility through 2027. Plant consolidations such as Hartalega's exit from Bestari Jaya underscore a sector-wide pivot toward fewer, more efficient sites to absorb price shocks.

Other drivers and restraints analyzed in the detailed report include:

1. Fast-Growing Ambulatory Surgery Network in Emerging APAC
2. Top-5 OEMs Scaling Biodegradable Low-Protein Latex Lines
3. OSHA-Driven Switch to Nitrile in U.S. Outpatient Clinics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Sterile gloves accounted for 67.34% of 2025 revenue, anchoring high-value contracts across surgical suites. This dominance in the latex medical gloves market reflects regulatory mandates that demand aseptic barriers and justifies ASPs that run USD 0.02-0.05 above non-sterile equivalents. Non-sterile gloves will nonetheless post a 7.87% CAGR as outpatient clinics and diagnostic labs expand, especially in emerging Asia. Shorter 4-6-week lead times give non-sterile producers agility that proved critical during pandemic disruptions.

Sterile production requires gamma irradiation or ethylene oxide cycles, adding capital intensity that favors scale players. Sri Trang's 2024 launch of a surgical line indicates the strategic pivot toward the 7.98% CAGR surgical segment. ISO 10282 and ISO 11193 distinctions prevent easy cross-over, preserving moats around specialist capacity. Examination of past shortages shows hospitals reluctant to trial off-brand sterile gloves because malpractice liabilities exceed USD 1 million per incident, reinforcing incumbents' grip on the latex medical gloves market.

Powder-free variants captured 70.12% share in 2025 and will grow at a 7.91% CAGR through 2031 as institutions phase out cornstarch-dusted alternatives banned by the FDA for surgical use in 2016. Production relies on chlorination or polymer coatings that raise costs 8-12%, yet these gloves meet low-dermatitis criteria prized by European tenders. Powdered gloves linger in veterinary and food service but will gradually cede ground.

Top Glove's ElastiCore accelerator-free line and SHOWA's FDA-cleared low-dermatitis glove demonstrate how product innovation supports premiums. A Thai clinical study showed symptomatic reactions falling from 9.8% to 1.2% after switching to low-protein powder-free gloves, validating hospital purchasing preferences. As procurement teams rationalize SKUs, inventory simplicity further tilts volume toward powder-free in the latex medical gloves market.

Complete Report Scope:

• By Product Type
  • Sterile Gloves
  • Non-sterile Gloves
• By Form
  • Powder-free Gloves
  • Powdered Gloves
• By Application
  • Examination Gloves
  • Surgical Gloves
• By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers
  • Diagnostic Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 40.01% share in 2025 as U.S. tariffs on Chinese gloves rose from 7.5% to 50% and will reach 100% in 2027, diverting orders to Malaysian and Thai producers. Hartalega captured roughly 13% of U.S. demand in FY 2026, and its sales now comprise 53% of group revenue. CMS incentives for U.S.-made nitrile cast uncertainty over latex imports, yet near-term supply gaps ensure continued inflows.

Asia-Pacific is the fastest-growing region at 8.01% CAGR, fueled by ASEAN's 685.4 million population and medical tourism revenue that could exceed USD 100 billion by 2029. Malaysia still supplies 45% of global output, but Chinese "+1" strategies in Vietnam and Indonesia face new U.S. tariffs of 46% and 32%, respectively, announced April 2025. India's production-linked incentives, reducing import reliance to 60% by FY 2024, signal growing domestic capacity.

Europe accounts for roughly one-fifth of demand; the EUDR adds USD 0.005-0.010 per glove for traceability, favoring vertically integrated suppliers. Middle East and Africa will expand 7.2-7.5% CAGR on over USD 50 billion GCC healthcare investment, yet fragmented logistics temper premium uptake. South America, led by Brazil, consumes 5-6% of global volume, with public tenders prioritizing low cost.

1. Ansell
2. Cardinal Health
3. Clean Q Grip
4. Dynarex
5. Hartalega Holdings
6. Kanam Latex Industries Pvt Ltd
7. Kimberly-Clark Worldwide
8. Kossan Rubber Industries
9. Mckesson
10. Medline Industries
11. Molnlycke Health Care
12. Riverstone Holdings Ltd
13. Rubberex Corporation (M) Bhd
14. Semperit
15. SHIELD Scientific
16. Showa Group
17. Solventum
18. Sri Trang Gloves (Thailand) PLC
19. Sunflower Ave
20. Supermax
21. Top Glove
22. UG Healthcare Corp. Ltd
23. Valutek
24. YTY Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support